RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo trial aims to reawaken immune system against stubborn lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination for people with B-cell lymphomas that have come back or stopped responding to other treatments. The treatment pairs an immunotherapy drug (nivolumab) with a pill (ASTX727) that may help the immun…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Double-Punch immune therapy aims to stop Lymphoma's return
Disease control Recruiting nowThis early-stage study is testing a two-part treatment to prevent aggressive B-cell lymphoma from coming back after a stem cell transplant. Doctors take a patient's own immune cells, modify them to target cancer, and infuse them back. They then give a vaccine designed to boost th…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Scientists test 'Double Punch' immune therapy to stop tough lymphoma
Disease control Recruiting nowThis early-stage study is testing the safety and feasibility of a two-part treatment for aggressive B-cell lymphoma that has come back or is not responding to other therapies. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and then infuse…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether a drug called loncastuximab tesirine can shrink tumors in adults with specific types of B-cell lymphoma that have come back or stopped responding to other treatments. The drug is designed to target cancer cells directly. Researchers will give the dru…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC